Journal article
High content, multi-parameter analyses in buccal cells to identify alzheimer’s disease
M François, MF Fenech, P Thomas, M Hor, A Rembach, RN Martins, SR Rainey-Smith, CL Masters, D Ames, CC Rowe, S Lance Macaulay, AF Hill, WR Leifert, A Appannah, M Barnes, K Barnham, J Bedo, S Bellingham, L Bon, P Bourgeat Show all
Current Alzheimer Research | Published : 2016
Abstract
Alzheimer’s disease (AD) is a degenerative brain disorder and is the most common form of dementia. Minimally invasive approaches are required that combine biomarkers to identify individuals who are at risk of developing mild cognitive impairment (MCI) and AD, to appropriately target clinical trials for therapeutic discovery as well as lifestyle strategies aimed at prevention. Buccal mucosa cells from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing cohort (n=60) were investigated for cytological markers that could be used to identify both MCI and AD individuals. Visual scoring of the buccal cytome demonstrated a significantly lower frequency of basal and karyorrhecti..
View full abstractGrants
Funding Acknowledgements
We thank the former president of Compucyte Corporation (Boston, MA, USA), Dr Elena Holden and her team, for helpful advice on establishing the iCyte protocol. We thank Theodora Almond and Candita Dang for assisting with the preparation of microscope slides. We thank all the participants who took part in this study and the clinicians who referred participants. The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) is a collaboration between CSIRO Australia, Edith Cowan University (Perth, Western Australia, Australia), The Florey Institute of Neuroscience and Mental Health (Melbourne, Victoria, Australia), National Ageing Research Institute and Austin Health (Parkville, Victoria, Australia). It also involves support from CogState Ltd. (Melbourne, Victoria, Australia), Hollywood Private Hospital and Sir Charles Gairdner Hospital (Nedlands, Western Australia, Australia). The AIBL study received funding support from the Science and Industry Endowment Fund, National Health and Medical Research Council (NHMRC) and Dementia Collaborative Research Centres (DCRC), Alzheimer's Australia and the McCusker Alzheimer's Research Foundation, as well as Industry, including Pfizer, Merck, Janssen and GE Healthcare. Financial support from the CSIRO's Preventative Health Flagship is gratefully acknowledged. WRL received a grant from The JO & JR Wicking Trust, which is managed by ANZ Trustees (Australia). The authors thank all the AIBL investigators (https://aibl.csiro.au/). The authors' contributions were as follows: MFF, MF and WRL designed the high content LSC research/study; MF prepared samples, MF and WRL designed the LSC protocol, MF conducted the automated analyses and collected data. AIBL administrative, technical, and material support as well as study supervision was provided by AR, CLM, RM, SR-S, CR, DA, AFH and LM. MF and WRL analyzed data and wrote the paper. All authors contributed to the final version of the paper.